Sender Co & Partners Inc. Grows Stock Position in Amgen Inc. (NASDAQ:AMGN)

Sender Co & Partners Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 74.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,217 shares of the medical research company’s stock after acquiring an additional 945 shares during the quarter. Amgen accounts for about 0.9% of Sender Co & Partners Inc.’s investment portfolio, making the stock its 23rd largest holding. Sender Co & Partners Inc.’s holdings in Amgen were worth $714,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in AMGN. Frisch Financial Group Inc. grew its stake in shares of Amgen by 8.1% during the third quarter. Frisch Financial Group Inc. now owns 1,093 shares of the medical research company’s stock valued at $352,000 after acquiring an additional 82 shares in the last quarter. Prestige Wealth Management Group LLC lifted its stake in shares of Amgen by 2.8% in the third quarter. Prestige Wealth Management Group LLC now owns 1,387 shares of the medical research company’s stock worth $447,000 after acquiring an additional 38 shares in the last quarter. Brophy Wealth Management LLC purchased a new position in Amgen in the third quarter valued at about $1,312,000. Conway Capital Management Inc. acquired a new stake in Amgen during the 3rd quarter valued at approximately $306,000. Finally, Resources Management Corp CT ADV increased its holdings in Amgen by 8.9% during the 3rd quarter. Resources Management Corp CT ADV now owns 5,065 shares of the medical research company’s stock worth $1,632,000 after purchasing an additional 415 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMGN. Redburn Partners reduced their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Sanford C. Bernstein started coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price for the company. Barclays upped their target price on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Finally, Dbs Bank upgraded Amgen to a “strong-buy” rating in a research note on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $323.05.

Amgen Stock Up 1.9 %

AMGN opened at $277.63 on Tuesday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a 12 month low of $257.80 and a 12 month high of $346.85. The stock’s 50 day moving average price is $305.69 and its 200 day moving average price is $315.66. The stock has a market cap of $149.23 billion, a P/E ratio of 35.55, a P/E/G ratio of 3.02 and a beta of 0.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.96 earnings per share. As a group, research analysts predict that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 9th. Investors of record on Monday, November 18th were paid a dividend of $2.25 per share. The ex-dividend date of this dividend was Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.24%. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.